Life Sciences Firms Embrace Modern Tools to Revolutionize Clinical Trials
3 Sources
3 Sources
[1]
Life Sciences Firms Adopt Tools to Modernize Clinical Trials
Digital transformation improves remote interactions with patients, streamlines research and analytics, ISG Provider Lensâ„¢ report says Technologies that enable decentralized clinical trials and other new practices are transforming the global life sciences industry, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report finds that enterprises are recognizing the limitations of traditional, centralized trials that require ongoing in-person visits by patients. Digital technologies now make it possible to remotely recruit patients, obtain their consent, monitor their health and collect data. "Interest in decentralized trials is soaring," said Jenn Stein, ISG partner and life sciences industry lead. "Pharmaceutical companies and research organizations are studying and embracing new methodologies to better evaluate treatments." The convergence of recent innovations in telemedicine, wearable devices, mobile applications and electronic health records has kickstarted this trend by enabling seamless remote interactions between patients and investigators, the report says. However, organizations are still working through challenges around data privacy, security, regulatory compliance and integration with existing trial infrastructure and workflows. AR and VR systems are becoming widely available for life sciences, and enterprises are introducing them to make it easier for patients to participate in decentralized trials, ISG says. Personalized patient engagement and training with these tools enhance comprehension and adherence to trial protocols. Organizations are also using AR and VR for more intuitive data visualization to analyze and interpret trial results. Enterprises and vendors are also innovating to provide more patient-centric research, trials and treatment outcomes, the report says. Getting patients involved in drug development and care delivery is a growing priority, and patient-reported outcomes are beginning to shape research and trials. Pharmaceutical companies, researchers and healthcare providers are collaborating with patients and communities to make sure products and services meet their needs. Organizations are using AI, automation and natural language processing (NLP) to change the way they conduct pharmacovigilance and regulatory compliance, ISG says. Automation is streamlining processes such as case intake and adverse event reporting, and AI algorithms let companies quickly analyze data, identify risks and respond to new regulations. Generative AI (GenAI) is the latest must-have technology. "There is a race to use GenAI to improve research and trials," said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. "Every company wants GenAI tools in its portfolio." The report also explores other trends in the life sciences industry, including the rising importance of supply chain management and collaborative approaches to regulation. For more insights into the challenges faced by life sciences organizations, including compliance with changing regulations and integration between new and legacy technologies, plus ISG's advice on overcoming these, see the ISG Provider Lensâ„¢ Focal Points briefing here. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report evaluates the capabilities of 39 providers across five quadrants: Clinical Development, Patient Engagement, Manufacturing Supply Chain, Pharmacovigilance and Regulatory Affairs -- Digital Evolution, and Commercial Operations -- Digital Evolution. The report names Accenture, Capgemini, Cognizant, Deloitte, HCLTech, Infosys and TCS as Leaders in all five quadrants. It names Wipro as a Leader in four quadrants and PPD as a Leader in three. Genpact, Hexaware and Tech Mahindra are named as Leaders in two quadrants each, and Indegene, IQVIA and LTIMindtree are named as leaders in one quadrant each. In addition, Tech Mahindra is named as a Rising Star -- a company with a "promising portfolio" and "high future potential" by ISG's definition -- in two quadrants. Hexaware, Indegene and Persistent Systems are named as Rising Stars in one quadrant each. In the area of customer experience, Cognizant is named the global ISG CX Star Performer for 2024 among life sciences digital services providers. Cognizant earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellenceâ„¢ program, the premier quality recognition for the technology and business services industry. Customized versions of the report are available from BeyondSoft, PPD and Tech Mahindra. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lensâ„¢ Research The ISG Provider Lensâ„¢ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world's top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including AI and automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries -- a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry's most comprehensive marketplace data. For more information, visit www.isg-one.com.
[2]
Life Sciences Firms Adopt Tools to Modernize Clinical Trials By Investing.com
Digital transformation improves remote interactions with patients, streamlines research and analytics, ISG Provider Lensâ„¢ report says STAMFORD, Conn.--(BUSINESS WIRE)--Technologies that enable decentralized clinical trials and other new practices are transforming the global life sciences industry, according to a new research report published today by Information Services Group (ISG) (Nasdaq: NASDAQ:III), a leading global technology research and advisory firm. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report finds that enterprises are recognizing the limitations of traditional, centralized trials that require ongoing in-person visits by patients. Digital technologies now make it possible to remotely recruit patients, obtain their consent, monitor their health and collect data. Interest in decentralized trials is soaring, said Jenn Stein, ISG partner and life sciences industry lead. Pharmaceutical companies and research organizations are studying and embracing new methodologies to better evaluate treatments. The convergence of recent innovations in telemedicine, wearable devices, mobile applications and electronic health records has kickstarted this trend by enabling seamless remote interactions between patients and investigators, the report says. However, organizations are still working through challenges around data privacy, security, regulatory compliance and integration with existing trial infrastructure and workflows. AR and VR systems are becoming widely available for life sciences, and enterprises are introducing them to make it easier for patients to participate in decentralized trials, ISG says. Personalized patient engagement and training with these tools enhance comprehension and adherence to trial protocols. Organizations are also using AR and VR for more intuitive data visualization to analyze and interpret trial results. Enterprises and vendors are also innovating to provide more patient-centric research, trials and treatment outcomes, the report says. Getting patients involved in drug development and care delivery is a growing priority, and patient-reported outcomes are beginning to shape research and trials. Pharmaceutical companies, researchers and healthcare providers are collaborating with patients and communities to make sure products and services meet their needs. Organizations are using AI, automation and natural language processing (NLP) to change the way they conduct pharmacovigilance and regulatory compliance, ISG says. Automation is streamlining processes such as case intake and adverse event reporting, and AI algorithms let companies quickly analyze data, identify risks and respond to new regulations. Generative AI (GenAI) is the latest must-have technology. There is a race to use GenAI to improve research and trials, said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. Every company wants GenAI tools in its portfolio. The report also explores other trends in the life sciences industry, including the rising importance of supply chain management and collaborative approaches to regulation. For more insights into the challenges faced by life sciences organizations, including compliance with changing regulations and integration between new and legacy technologies, plus ISG's advice on overcoming these, see the ISG Provider Lensâ„¢ Focal Points briefing here. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report evaluates the capabilities of 39 providers across five quadrants: Clinical Development, Patient Engagement, Manufacturing Supply Chain, Pharmacovigilance and Regulatory Affairs " Digital Evolution, and Commercial Operations " Digital Evolution. The report names Accenture (NYSE:ACN), Capgemini, Cognizant (NASDAQ:CTSH), Deloitte, HCLTech, Infosys (NS:INFY) and TCS as Leaders in all five quadrants. It names Wipro (NYSE:WIT) as a Leader in four quadrants and PPD (NASDAQ:PPD) as a Leader in three. Genpact (NYSE:G), Hexaware and Tech Mahindra are named as Leaders in two quadrants each, and Indegene, IQVIA and LTIMindtree (NS:LTIM) are named as leaders in one quadrant each. In addition, Tech Mahindra is named as a Rising Star " a company with a promising portfolio and high future potential by ISG's definition " in two quadrants. Hexaware, Indegene and Persistent Systems are named as Rising Stars in one quadrant each. In the area of customer experience, Cognizant is named the global ISG CX Star Performer for 2024 among life sciences digital services providers. Cognizant earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellenceâ„¢ program, the premier quality recognition for the technology and business services industry. Customized versions of the report are available from BeyondSoft, PPD and Tech Mahindra. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lensâ„¢ Research The ISG Provider Lensâ„¢ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world's top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including AI and automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries"a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry's most comprehensive marketplace data. For more information, visit www.isg-one.com.
[3]
Life Sciences Firms Adopt Tools to Modernize Clinical Trials - Information Servs Gr (NASDAQ:III)
Digital transformation improves remote interactions with patients, streamlines research and analytics, ISG Provider Lensâ„¢ report says Technologies that enable decentralized clinical trials and other new practices are transforming the global life sciences industry, according to a new research report published today by Information Services Group (ISG) III, a leading global technology research and advisory firm. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report finds that enterprises are recognizing the limitations of traditional, centralized trials that require ongoing in-person visits by patients. Digital technologies now make it possible to remotely recruit patients, obtain their consent, monitor their health and collect data. "Interest in decentralized trials is soaring," said Jenn Stein, ISG partner and life sciences industry lead. "Pharmaceutical companies and research organizations are studying and embracing new methodologies to better evaluate treatments." The convergence of recent innovations in telemedicine, wearable devices, mobile applications and electronic health records has kickstarted this trend by enabling seamless remote interactions between patients and investigators, the report says. However, organizations are still working through challenges around data privacy, security, regulatory compliance and integration with existing trial infrastructure and workflows. AR and VR systems are becoming widely available for life sciences, and enterprises are introducing them to make it easier for patients to participate in decentralized trials, ISG says. Personalized patient engagement and training with these tools enhance comprehension and adherence to trial protocols. Organizations are also using AR and VR for more intuitive data visualization to analyze and interpret trial results. Enterprises and vendors are also innovating to provide more patient-centric research, trials and treatment outcomes, the report says. Getting patients involved in drug development and care delivery is a growing priority, and patient-reported outcomes are beginning to shape research and trials. Pharmaceutical companies, researchers and healthcare providers are collaborating with patients and communities to make sure products and services meet their needs. Organizations are using AI, automation and natural language processing (NLP) to change the way they conduct pharmacovigilance and regulatory compliance, ISG says. Automation is streamlining processes such as case intake and adverse event reporting, and AI algorithms let companies quickly analyze data, identify risks and respond to new regulations. Generative AI (GenAI) is the latest must-have technology. "There is a race to use GenAI to improve research and trials," said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. "Every company wants GenAI tools in its portfolio." The report also explores other trends in the life sciences industry, including the rising importance of supply chain management and collaborative approaches to regulation. For more insights into the challenges faced by life sciences organizations, including compliance with changing regulations and integration between new and legacy technologies, plus ISG's advice on overcoming these, see the ISG Provider Lensâ„¢ Focal Points briefing here. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report evaluates the capabilities of 39 providers across five quadrants: Clinical Development, Patient Engagement, Manufacturing Supply Chain, Pharmacovigilance and Regulatory Affairs -- Digital Evolution, and Commercial Operations -- Digital Evolution. The report names Accenture, Capgemini, Cognizant, Deloitte, HCLTech, Infosys and TCS as Leaders in all five quadrants. It names Wipro as a Leader in four quadrants and PPD as a Leader in three. Genpact, Hexaware and Tech Mahindra are named as Leaders in two quadrants each, and Indegene, IQVIA and LTIMindtree are named as leaders in one quadrant each. In addition, Tech Mahindra is named as a Rising Star -- a company with a "promising portfolio" and "high future potential" by ISG's definition -- in two quadrants. Hexaware, Indegene and Persistent Systems are named as Rising Stars in one quadrant each. In the area of customer experience, Cognizant is named the global ISG CX Star Performer for 2024 among life sciences digital services providers. Cognizant earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellenceâ„¢ program, the premier quality recognition for the technology and business services industry. Customized versions of the report are available from BeyondSoft, PPD and Tech Mahindra. The 2024 ISG Provider Lensâ„¢ global Life Sciences Digital Services report is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lensâ„¢ Research The ISG Provider Lensâ„¢ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Information Services Group) III is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world's top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including AI and automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries -- a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry's most comprehensive marketplace data. For more information, visit www.isg-one.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240716714144/en/ Market News and Data brought to you by Benzinga APIs
Share
Copy Link
A new study reveals that life sciences organizations are increasingly adopting innovative technologies to streamline clinical trials. The trend shows a shift towards more efficient, patient-centric approaches in drug development and medical research.
Modernization of Clinical Trials
Life sciences firms are increasingly turning to advanced technologies to modernize clinical trials, according to a recent study by Information Services Group (ISG). The ISG Provider Lensâ„¢ Life Sciences Digital Services report for 2023 highlights a significant shift in the industry towards more efficient and patient-centric approaches in drug development and medical research 1.
Key Drivers of Change
The COVID-19 pandemic has been a major catalyst for this transformation, accelerating the adoption of digital technologies in clinical trials. Life sciences companies are now leveraging tools such as artificial intelligence (AI), machine learning, and data analytics to enhance various aspects of the clinical trial process 2.
Emerging Technologies in Clinical Trials
Several innovative technologies are being employed to improve clinical trials:
- Decentralized Clinical Trials (DCTs): These allow participants to join studies remotely, increasing accessibility and diversity in trial populations.
- Real-World Evidence (RWE): Utilizing real-world data to complement traditional clinical trial data for more comprehensive insights.
- AI and Machine Learning: These technologies are being used to optimize trial design, patient recruitment, and data analysis.
- Digital Health Technologies: Wearables and mobile apps are enabling continuous patient monitoring and data collection 3.
Benefits of Modernization
The adoption of these technologies is yielding significant benefits:
- Improved patient engagement and retention
- More diverse and representative patient populations
- Faster and more efficient trial processes
- Enhanced data quality and analysis capabilities
- Reduced costs and time-to-market for new treatments
Challenges and Considerations
Despite the advantages, the industry faces challenges in implementing these new technologies:
- Data privacy and security concerns
- Regulatory compliance in a rapidly evolving landscape
- Integration of new technologies with existing systems
- Training and upskilling of workforce to utilize advanced tools
Industry Outlook
The ISG report predicts continued growth in the adoption of digital technologies for clinical trials. Life sciences firms are expected to increasingly partner with technology providers to leverage expertise in areas such as AI, data analytics, and cloud computing 1.
As the industry moves forward, the focus will be on creating more patient-centric, efficient, and data-driven clinical trials. This shift is expected to accelerate drug development timelines and improve the overall quality of medical research, ultimately benefiting patients worldwide.
Summarized by
Navi
[1]
Netflix Pioneers Use of Generative AI in Original Content Production
Netflix has incorporated generative AI technology in its original series "El Eternauta," marking a significant shift in content production methods for the streaming giant.
23 Sources
Technology
15 hrs ago
23 Sources
Technology
15 hrs ago
Meta Refuses to Sign EU's AI Code of Practice, Citing Overreach and Innovation Concerns
Meta declines to sign the European Union's voluntary AI code of practice, calling it an overreach that could stifle innovation and economic growth in Europe. The decision highlights growing tensions between tech giants and EU regulators over AI governance.
13 Sources
Policy and Regulation
14 hrs ago
13 Sources
Policy and Regulation
14 hrs ago
OpenAI Advisory Board Recommends Continued Nonprofit Oversight for AI Development
An advisory board convened by OpenAI recommends that the company should continue to be controlled by a nonprofit, emphasizing the need for democratic participation in AI development and governance.
6 Sources
Policy and Regulation
15 hrs ago
6 Sources
Policy and Regulation
15 hrs ago
Perplexity AI Surges in India, Challenging ChatGPT's Dominance
Perplexity AI partners with Airtel to offer free Pro subscriptions, leading to a significant increase in downloads and user base in India, potentially reshaping the AI search landscape.
5 Sources
Technology
15 hrs ago
5 Sources
Technology
15 hrs ago
Perplexity AI Secures $100 Million Funding, Reaching $18 Billion Valuation
Perplexity AI, an AI-powered search engine startup, has raised $100 million in a new funding round, valuing the company at $18 billion. This development highlights the growing investor interest in AI startups and Perplexity's potential to challenge Google's dominance in internet search.
4 Sources
Startups
15 hrs ago
4 Sources
Startups
15 hrs ago
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
